SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cash Cat

Cash Cat is trending as market participants speculate on its role as a leading meme coin following its listing on Robinhood, with many investors actively discussing its potential for a massive rally similar to other high-profile meme tokens. While some community members are bullishly accumulating the asset, others express caution and skepticism regarding its volatility and the sustainability of the hype surrounding the exchange-related narrative.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors debate its long-term potential compared to established memecoins, with discussions split between those citing strong brand partnerships and those frustrated by persistent price volatility. Market sentiment remains polarized, as many participants weigh technical price resistance levels against the broader anticipation of a crypto market rebound.

Talon Metals Corp. engages in the exploration and development of mineral properties. It holds interests in the Tamarack nickel-copper-cobalt and Trairão iron projects. The company was founded on April 5, 2005 and is headquartered in Road Town, British Virgin Islands.

Talon Metals Corp

Talon Metals is attracting significant attention as community members analyze recent record-breaking drill intercepts at the Vault Zone and speculate on potential regulatory catalysts and government involvement in critical mineral supply chains. Investors are actively discussing the stock's recent price momentum and high trading volume, framing these developments as a potential precursor to long-term growth and supply chain importance.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors digest the company's recent operational progress at its Groves Isotope Test Reactor and the anticipation surrounding its upcoming earnings call. The community is sharply divided, with bulls highlighting the potential of the nuclear sector to meet AI power demands and achieve criticality, while bears remain skeptical of the company's pre-revenue status and the impact of continued share offerings.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is currently trending as investors anticipate upcoming earnings and potential major pharmaceutical manufacturing partnerships linked to U.S. drug onshoring mandates. The community is actively discussing the company's strategic pivot into pharmaceutical components and the potential for a significant stock repricing driven by regulatory shifts and manufacturing capacity.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as investors aggressively position in the stock ahead of its earnings report, driven by analyst upgrades and strong community conviction that it remains a critical play in the AI infrastructure buildout. Market participants are actively debating whether its recent price action signals a breakout to all-time highs or a potential consolidation, with bulls pointing to robust demand for high-speed networking hardware as a core catalyst.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

TransMedics is trending as investors weigh strong long-term growth prospectsdriven by OCS organ transplantation technology and international expansionagainst short-term margin pressures and volatility linked to operational spending. While some market participants express concern over earnings volatility and fuel costs, the community remains heavily focused on the company's ability to scale procedure volumes and capitalize on its expanding logistics infrastructure.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is currently attracting investor attention as the community debates its long-term potential for institutional utility versus ongoing concerns regarding token dilution and price performance. While some participants are actively accumulating during current price levels in anticipation of a potential breakthrough fueled by the Clarity Act and broader institutional adoption, others remain skeptical due to the asset's persistent sideways trading and the ongoing release of locked tokens.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

The JNUG ETF is currently drawing significant community attention due to heightened concerns over global fiscal instability, record-breaking national debt, and intensifying geopolitical tensions in key energy transit regions. Investors are leveraging the fund to gain exposure to gold mining stocks as they increasingly view precious metals as a necessary hedge against deteriorating fiat currency purchasing power and systemic inflationary risks.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market attention driven by a combination of strategic growth initiatives, such as its $1.5 billion acquisition of Personalis, and a high volume of institutional and retail interest surrounding its positioning in AI-driven precision medicine. Community discussions are highly polarized, with many investors actively debating whether the stock is a long-term play on healthcare data infrastructure or a volatile asset currently facing heavy short pressure and integration risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness and debate the company's potential as a buyout target for major pharmaceutical firms. The community is actively discussing the firm's strategic focus on GLP-1 adjunct treatments and pipeline developments while balancing optimism against frustrations over persistent price volatility.

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results PR Newswire WASHINGTON, Aug. 5, 2026 Fanapt Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%Full-year 2026 total revenue...

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire WASHINGTON, July 29, 2026 Conference Call and Webcast to FollowWASHINGTON, July 29, 2026 /PRNewswire...

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab...

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire WASHINGTON, July 15, 2026 WASHINGTON, July...

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire WASHINGTON, July 10, 2026 WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda...

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Equity

The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S. 


Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PR Newswire...

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PR Newswire WASHINGTON, May 27, 2026 WASHINGTON, May 27, 2026...

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire WASHINGTON, May 7, 2026...

$VNDA Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.04 down -126.09% YoY
• Reported revenue of $1.03M down -98.04% YoY
• Vanda Pharmaceuticals Inc. is reiterating its 2026 total revenue guidance of $240 million to $290 million and expects to achieve various financial objectives across its product portfolio throughout the year.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VNDAVanda Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest VNDA News